Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience

Leukemia Research ◽

10.1016/j.leukres.2020.106314 ◽

2020 ◽

Vol 90 ◽

pp. 106314 ◽

Author(s):

Daria Gaut ◽

Aaron Burkenroad ◽

Tuyen Duong ◽

Jesse Feammelli ◽

Joshua Sasine ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Combination Therapy ◽

Myeloid Leukemia ◽

Single Institution ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

American Journal of Hematology ◽

10.1002/ajh.25000 ◽

2017 ◽

Vol 93 (3) ◽

pp. 401-407 ◽

Author(s):

Courtney D. DiNardo ◽

Caitlin R. Rausch ◽

Christopher Benton ◽

Tapan Kadia ◽

Nitin Jain ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Combination Therapy ◽

Clinical Experience ◽

Myeloid Leukemia ◽

Myeloid Malignancies ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-2586 ◽

2020 ◽

Vol 26 (23) ◽

pp. 6132-6140

Author(s):

Amer M. Zeidan ◽

Maya Ridinger ◽

Tara L. Lin ◽

Pamela S. Becker ◽

Gary J. Schiller ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Combination Therapy ◽

Myeloid Leukemia ◽

Phase Ib ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1742897 ◽

2020 ◽

Vol 61 (8) ◽

pp. 1965-1973 ◽

Author(s):

Eunice S. Wang ◽

Richard Aplenc ◽

Deborah Chirnomas ◽

Michael Dugan ◽

Salman Fazal ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Combination Therapy ◽

Myeloid Leukemia ◽

Gemtuzumab Ozogamicin ◽

Access Protocol ◽

Expanded Access ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes

Leukemia & Lymphoma ◽

10.1080/10428194.2021.2012667 ◽

2021 ◽

pp. 1-5

Author(s):

Gail J. Roboz ◽

Karen Yee ◽

Amit Verma ◽

Gautam Borthakur ◽

Adolfo de la Fuente Burguera ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

High Risk ◽

Combination Therapy ◽

Phase I ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Phase I Trials ◽

Lysine Specific Demethylase ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Long-term survival case reports of two pediatric relapsed or refractory acute myeloid leukemia patients treated with bisantrene combination therapy

Journal of Clinical & Experimental Pathology ◽

10.4172/2161-0681-c1-046 ◽

2018 ◽

Vol 08 ◽

Author(s):

Amir Sharaf

Keyword(s):

Acute Myeloid Leukemia ◽

Combination Therapy ◽

Myeloid Leukemia ◽

Case Reports ◽

Term Survival ◽

Long Term Survival ◽

Refractory Acute Myeloid Leukemia ◽

Acute Myeloid ◽

Download Full-text

13 / MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study.

10.26226/morressier.5b3b802cb1b87b000eced984 ◽

2018 ◽

Author(s):

Maiti Abhishek

Keyword(s):

Acute Myeloid Leukemia ◽

Phase I ◽

Myeloid Leukemia ◽

Mek Inhibitor ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Case Medical Research ◽

10.31525/ct1-nct04240002 ◽

2020 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Young Adults ◽

Tyrosine Kinase ◽

Myeloid Leukemia ◽

Tandem Duplication ◽

Adolescents And Young Adults ◽

Internal Tandem Duplication ◽

Refractory Acute Myeloid Leukemia ◽

Flt3 Internal Tandem Duplication ◽

Download Full-text

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Case Medical Research ◽

10.31525/ct1-nct04207190 ◽

2019 ◽

Author(s):

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Gemtuzumab Ozogamicin ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Sequential Azacitidine and Lenalidomide for Patients with Relapsed and Refractory Acute Myeloid Leukemia: Clinical Results and Predictive Modeling Using Computational Analysis

SSRN Electronic Journal ◽

10.2139/ssrn.3307702 ◽

2018 ◽

Author(s):

Brett Stevens ◽

Amanda Winters ◽

Jonathan A. Gutman ◽

Aaron Fullerton ◽

Gregory Hemenway ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Predictive Modeling ◽

Myeloid Leukemia ◽

Computational Analysis ◽

Clinical Results ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text

Pooled Clinical Safety Analysis of CPX-351 Versus Conventional Chemotherapy in Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2019.07.084 ◽

2019 ◽

Vol 19 ◽

pp. S214-S215

Author(s):

Jorge E. Cortes ◽

Robert J. Ryan ◽

Michael Chiarella

Keyword(s):

Acute Myeloid Leukemia ◽

Myeloid Leukemia ◽

Safety Analysis ◽

Newly Diagnosed ◽

Conventional Chemotherapy ◽

Clinical Safety ◽

Refractory Acute Myeloid Leukemia ◽

Download Full-text